New and Emerging Therapies for Uterine Fibroids

Kate Fritton, Mostafa A. Borahay

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The pain, bleeding, and anemia associated with uterine fibroids debilitate many women. In addition to limited efficacy, the side effects of the currently used medical therapies prevent long-term use and nearly all pregnancies. Thus, women hoping to achieve pregnancy have limited options and usually opt for myomectomy. Once completed childbearing, many patients proceed with hysterectomy despite its risks and costs. Thus, there is a clear need for a new medical treatment for fibroids that is safe and effective. To this end, researchers have investigated several new treatments over the recent years, including both hormonal and nonhormonal ones. Some examples include selective progesterone receptor modulators, vitamin D, aromatase inhibitors, gene therapy, simvastatin, nanoparticles, epigallocatechin gallate, and intratumor collagenase injections. The aim of this article is to review and critically analyze the evidence (both laboratory and clinical) for these emerging therapies. We will discuss strengths and weaknesses of studies, areas where further evidence is needed, and finally deliberate on novel targets potentially amenable for development of future therapeutics.

Original languageEnglish (US)
Pages (from-to)549-559
Number of pages11
JournalSeminars in Reproductive Medicine
Volume35
Issue number6
DOIs
StatePublished - Nov 1 2017
Externally publishedYes

Fingerprint

Leiomyoma
Uterine Myomectomy
Therapeutics
Pregnancy
Aromatase Inhibitors
Simvastatin
Collagenases
Progesterone Receptors
Hysterectomy
Vitamin D
Genetic Therapy
Nanoparticles
Anemia
Research Personnel
Hemorrhage
Costs and Cost Analysis
Pain
Injections

Keywords

  • fibroids
  • leiomyoma
  • novel
  • therapy
  • treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Reproductive Medicine
  • Endocrinology
  • Obstetrics and Gynecology
  • Physiology (medical)

Cite this

New and Emerging Therapies for Uterine Fibroids. / Fritton, Kate; Borahay, Mostafa A.

In: Seminars in Reproductive Medicine, Vol. 35, No. 6, 01.11.2017, p. 549-559.

Research output: Contribution to journalArticle

Fritton, Kate ; Borahay, Mostafa A. / New and Emerging Therapies for Uterine Fibroids. In: Seminars in Reproductive Medicine. 2017 ; Vol. 35, No. 6. pp. 549-559.
@article{048126f5088f4c008d0128ca73142797,
title = "New and Emerging Therapies for Uterine Fibroids",
abstract = "The pain, bleeding, and anemia associated with uterine fibroids debilitate many women. In addition to limited efficacy, the side effects of the currently used medical therapies prevent long-term use and nearly all pregnancies. Thus, women hoping to achieve pregnancy have limited options and usually opt for myomectomy. Once completed childbearing, many patients proceed with hysterectomy despite its risks and costs. Thus, there is a clear need for a new medical treatment for fibroids that is safe and effective. To this end, researchers have investigated several new treatments over the recent years, including both hormonal and nonhormonal ones. Some examples include selective progesterone receptor modulators, vitamin D, aromatase inhibitors, gene therapy, simvastatin, nanoparticles, epigallocatechin gallate, and intratumor collagenase injections. The aim of this article is to review and critically analyze the evidence (both laboratory and clinical) for these emerging therapies. We will discuss strengths and weaknesses of studies, areas where further evidence is needed, and finally deliberate on novel targets potentially amenable for development of future therapeutics.",
keywords = "fibroids, leiomyoma, novel, therapy, treatment",
author = "Kate Fritton and Borahay, {Mostafa A.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1055/s-0037-1606303",
language = "English (US)",
volume = "35",
pages = "549--559",
journal = "Seminars in Reproductive Medicine",
issn = "1526-8004",
publisher = "Thieme Medical Publishers",
number = "6",

}

TY - JOUR

T1 - New and Emerging Therapies for Uterine Fibroids

AU - Fritton, Kate

AU - Borahay, Mostafa A.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The pain, bleeding, and anemia associated with uterine fibroids debilitate many women. In addition to limited efficacy, the side effects of the currently used medical therapies prevent long-term use and nearly all pregnancies. Thus, women hoping to achieve pregnancy have limited options and usually opt for myomectomy. Once completed childbearing, many patients proceed with hysterectomy despite its risks and costs. Thus, there is a clear need for a new medical treatment for fibroids that is safe and effective. To this end, researchers have investigated several new treatments over the recent years, including both hormonal and nonhormonal ones. Some examples include selective progesterone receptor modulators, vitamin D, aromatase inhibitors, gene therapy, simvastatin, nanoparticles, epigallocatechin gallate, and intratumor collagenase injections. The aim of this article is to review and critically analyze the evidence (both laboratory and clinical) for these emerging therapies. We will discuss strengths and weaknesses of studies, areas where further evidence is needed, and finally deliberate on novel targets potentially amenable for development of future therapeutics.

AB - The pain, bleeding, and anemia associated with uterine fibroids debilitate many women. In addition to limited efficacy, the side effects of the currently used medical therapies prevent long-term use and nearly all pregnancies. Thus, women hoping to achieve pregnancy have limited options and usually opt for myomectomy. Once completed childbearing, many patients proceed with hysterectomy despite its risks and costs. Thus, there is a clear need for a new medical treatment for fibroids that is safe and effective. To this end, researchers have investigated several new treatments over the recent years, including both hormonal and nonhormonal ones. Some examples include selective progesterone receptor modulators, vitamin D, aromatase inhibitors, gene therapy, simvastatin, nanoparticles, epigallocatechin gallate, and intratumor collagenase injections. The aim of this article is to review and critically analyze the evidence (both laboratory and clinical) for these emerging therapies. We will discuss strengths and weaknesses of studies, areas where further evidence is needed, and finally deliberate on novel targets potentially amenable for development of future therapeutics.

KW - fibroids

KW - leiomyoma

KW - novel

KW - therapy

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85032836810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032836810&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1606303

DO - 10.1055/s-0037-1606303

M3 - Article

VL - 35

SP - 549

EP - 559

JO - Seminars in Reproductive Medicine

JF - Seminars in Reproductive Medicine

SN - 1526-8004

IS - 6

ER -